Serina Therapeutics opened lower at $1.47, compared with its previous close of $1.89. In the last trading session, the stock traded between $1.47 and $2.55. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Serina Therapeutics is now worth
$ 11.83
resulting in a loss of
$ 88.17 (88.17%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.13 (-6.88%)
Day High
$2.55
Day Low
$1.47
Day Open
$1.47
Prev Close
$1.89
Volume
1,32,637
1W Return
-0.56%
1M Return
-13.34%
3M Return
-16.19%
6M Return
-3.83%
1Y Return
-62.63%
Market Cap ($ Mn)
45
PE Ratio
-
PB Ratio
3.34
PEG Ratio
-
ROE
-
ROCE
-449.24%
EPS (TTM)
-
1 Week
-0.56%
1 Month
-13.34%
3 Months
-16.19%
6 Months
-3.83%
9 Months
-50.28%
Serina Therapeutics files prospectus for 12.5m share sale by Roth
Serina Therapeutics filed a prospectus with the SEC. The filing covers the sale of up to 12,500,000 shares. Roth Principal Investments is the selling entity.
2mo agoSerina Therapeutics Q2 loss widens to $(0.55) as revenue drops to zero
Serina Therapeutics reported a Q2 2026 net loss of $8.9 million, missing analyst estimates, as revenue dropped to zero from $130,000 in the prior year. Operating expenses rose 19% to $6.8 million due to increased R&D and G&A costs. However, cash reserves surged to $23.0 million following a PIPE financing, providing extended runway. Clinically, the company completed Cohort 1 dosing for its lead Parkinson's drug SER-252 ahead of schedule, with top-line data expected in H1 2027.
2mo agoSerina Therapeutics completes SER-252 dosing ahead of Q3 2026 guidance
Serina Therapeutics completed enrollment and dosing for Cohort 1 of its Phase 1b registrational trial for SER-252 in advanced Parkinson’s disease, finishing ahead of its Q3 2026 target. The trial involves eight patients across sites in the US and Australia, with an Independent Safety Monitoring Committee set to review safety data to inform dose-escalation decisions.
3mo agoSerina Therapeutics appoints Dr. Farrell Simon to its Board
Serina Therapeutics, Inc. has appointed Dr. Farrell Simon to its Board of Directors and its Audit and Compensation Committees. Dr. Simon brings extensive experience from his roles at Trevi Therapeutics and Pfizer. The company is advancing its SER-252 program for Parkinson’s disease and expanding its POZ Platform technology.
3mo agoSerina Therapeutics completes sentinel dosing in SER-252 trial
Serina Therapeutics completed sentinel dosing in Cohort 1 of its Phase 1b registrational trial for SER-252 in advanced Parkinson’s disease. The independent Safety Monitoring Committee reviewed initial safety data and recommended continued dosing. The company now expects to complete Cohort 1 enrollment and dosing ahead of its previous guidance of the end of the third quarter of 2026.
3mo agoBTIG initiates coverage on Serina Therapeutics with Buy rating
BTIG analyst Thomas Shrader initiated coverage on Serina Therapeutics with a Buy rating and a price target of $8, indicating a positive outlook for the stock.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 3 years ago in Serina Therapeutics is now worth
$ 11.83
resulting in a loss of
$ 88.17 (88.17%)
Note: Past profits do not guarantee future returns.
